A practical reference on albumin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-28. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
=== Other medicines === Other treatments include lindane, benzyl benzoate, crotamiton, malathion, and sulfur preparations. Lindane is effective, but concerns over potential neurotoxicity have limited its availability in many countries. It is banned in California, but may be used in other states as a second-line treatment. Sulfur ointments or benzyl benzoate are often used in the developing world due to their low cost; some 10% sulfur solutions have been shown to be effective, and sulfur ointments are typically used for at least a week, though many people find the odor of sulfur products unpleasant. Crotamiton has been found to be less effective than permethrin in limited studies. Crotamiton or sulfur preparations are sometimes recommended instead of permethrin for children, due to concerns over dermal absorption of permethrin.
Pseudoacromegaly is a condition with the usual acromegaloid features but without an increase in growth hormone and IGF-1. It is frequently associated with insulin resistance. Cases have been reported due to minoxidil at an unusually high dose. It can also be caused by a selective post-receptor defect of insulin signalling, leading to the impairment of metabolic, but preservation of mitogenic, signaling. Treatment options include surgery to remove the tumor, medications, and radiation therapy. Surgery is usually the preferred treatment; the smaller the tumor, the more likely surgery will be curative. If surgery is contraindicated or not curative, somatostatin analogues or GH receptor antagonists may be used. Radiation therapy may be used if neither surgery nor medications are completely effective. Without treatment, life expectancy is reduced by 10 years; with treatment, life expectancy is not reduced.
== Sodium-23 == Sodium-23 is the sole natural isotope of sodium, with an atomic mass of 22.98976928. Because of this, sodium-23 is used in nuclear magnetic resonance in various research fields, including materials science and battery research. Sodium-23 relaxation has applications in studying cation-biomolecule interactions, intracellular and extracellular sodium, ion transport in batteries, and quantum information processing.
A meta-analysis conducted in 2007 and updated in 2020 by the international Cochrane Collaboration, which reviewed numerous randomized controlled trials, found that treatment with glargine and detemir insulins resulted in fewer cases of hypoglycemia compared to NPH insulin. Additionally, treatment with detemir was associated with a reduction in the frequency of severe hypoglycemia. However, the review acknowledged limitations, such as the use of low glucose and Hemoglobin A1c targets, which could affect the generalizability of these findings to routine clinical practice. In 2007, a report from Germany's Institute for Quality and Cost Effectiveness in the Health Care Sector (IQWiG) concluded that there was insufficient evidence to support the superiority of short-acting insulin analogues over synthetic human insulin for the treatment of adult patients with type 1 diabetes. Many of the studies reviewed were criticized for being too small to provide statistically reliable results, and notably, none were blinded.
Sources: en.wikipedia.org
Several national and regional radio stations are relays for Le Havre: local information on France Bleu Haute Normandie, local relay from 12 noon to 4pm on Virgin radio Normandie 101.8 FM, local relay for Information from 6am to 9am and from 4pm to 8pm on NRJ Le Havre 92.5 FM. Associations like LHnouslanuit and Only-Hit have tried to develop alternative and cultural local radio by featuring local community associations (Papa's Production, Ben Salad Prod, Asso6Sons, Agend'Havre, Pied Nu, I Love LH).
=== Nucleoplasmic extract (NPE) === Nucleoplasmic extract (NPE) is prepared from Xenopus egg extracts by first assembling nuclei in S-phase extract through the addition of a high concentration of sperm chromatin (~10,000 nuclei per μL). The reaction mixture is then centrifuged without dilution to separate the nuclei, which form a distinct layer at the top. This nuclear fraction is collected and further centrifuged at high speed, yielding a soluble supernatant (nucleoplasm) and a pellet containing nuclear membranes and chromatin. The supernatant is referred to as the nucleoplasmic extract (NPE). When DNA is pre-incubated in S-phase HSS and then NPE is added, DNA replication can be initiated without the need for nuclear envelope formation—a significant distinction from standard S-phase extract protocols, where replication initiation requires nuclear assembly. This system has enabled high-resolution analysis of replication initiation mechanisms. Moreover, NPE supports efficient replication of plasmid DNA and other non-sperm-derived templates. Leveraging this property, researchers have also used NPE to investigate DNA repair pathways using exogenously damaged DNA substrates.
Seeded 13th, he earned his first victory over Alexander Bublik by beating him in the first round in three sets. In the second round, he defeated world No. 29, Roberto Bautista Agut, in the second round. In the third round, he lost to third seed, Daniil Medvedev, despite serving for the match twice and having two match points in the third-set tie-break. This defeat was his seventh out of the last eight matches played with Medvedev. Seeded third at the BMW Open in Munich, he was defeated in the second round by Christopher O'Connell. Seeded 13th at the Madrid Open, he recorded his 350th career win by defeating Roberto Carballés Baena in the second round, becoming the only player under 30 to reach this milestone. In the third round, he overpowered qualifier, Hugo Grenier, in 55 minutes. In the fourth round, he lost to top seed, world No. 2, defending champion, and eventual champion, Carlos Alcaraz, in a rematch of the previous year's final. Failing to defend his finalist points from last year, his ranking fell from 16 to 22. Seeded 19th at the Italian Open, he made it to the fourth round where he lost to third seed and eventual champion, Daniil Medvedev. Having made the semifinals last year, his ranking again fell, this time from 22 to 27. Seeded third at the Geneva Open, he reached the semifinal where he lost to Nicolás Jarry, who would end up winning the tournament. Seeded 22nd at the French Open, he defeated Lloyd Harris, Alex Molčan, 12th seed Frances Tiafoe, and 28th seed Grigor Dimitrov in his first four rounds. In the quarterfinals, he faced Tomás Martín Etcheverry.
Sources: en.wikipedia.org
== External links == Databases Drug metabolism database Directory of P450-containing Systems Drug metabolism Drug metabolism portal Small Molecule Drug Metabolism "Activation, Metabolic". Medical Subject Headings. National Library of Medicine. MeSH D065767. Retrieved 2026-05-24. "Inactivation, Metabolic". Medical Subject Headings. National Library of Medicine. MeSH D008658. Retrieved 2026-05-24. "Biotransformation". Medical Subject Headings. National Library of Medicine. MeSH D001711. Retrieved 2026-05-24.
A hidden Markov model (HMM) is applied as a new way to solve de novo sequencing in a Bayesian framework. Instead of scoring for single symbols of the sequence, this method considers posterior probabilities for amino acids. In the paper, this method is proved to have better performance than other popular de novo peptide sequencing methods like PepNovo by a lot of example spectra. PEAKS is a complete software package for the interpretation of peptide mass spectra. It contains de novo sequencing, database search, PTM identification, homology search and quantification in data analysis. Ma et al. described a new model and algorithm for de novo sequencing in PEAKS, and compared the performance with Lutefisk of several tryptic peptides of standard proteins, by the quadrupole time-of-flight (Q-TOF) mass spectrometer. PepNovo is a high throughput de novo peptide sequencing tool and uses a probabilistic network as scoring method. It usually takes less than 0.2 seconds for interpretation of one spectrum. Described by Frank et al., PepNovo works better than several popular algorithms like Sherenga, PEAKS, Lutefisk. Now a new version PepNovo+ is available. Chi et al. presented pNovo+ in 2013 as a new de novo peptide sequencing tool by using complementary HCD and ETD tandem mass spectra. In this method, a component algorithm, pDAG, largely speeds up the acquisition time of peptide sequencing to 0.018s on average, which is three times as fast as the other popular de novo sequencing software.
==== Supermarkets ==== The third and final change to US food distribution in the first half of the 20th century involved the establishment of supermarkets. The Ford Motor Company performed the first experiment regarding the profitability of large-scale supermarkets after the end of World War I. Supermarkets officially began gaining prominence in the 1930s and steadily continued their growth into the post-WWII era.
=== Bulk foams and aerogels === Nanocellulose can also be used to make aerogels/foams, either homogeneously or in composite formulations. Nanocellulose-based foams are being studied for packaging applications in order to replace polystyrene-based foams. Svagan et al. showed that nanocellulose has the ability to reinforce starch foams by using a freeze-drying technique. The advantage of using nanocellulose instead of wood-based pulp fibers is that the nanofibrils can reinforce the thin cells in the starch foam. Moreover, it is possible to prepare pure nanocellulose aerogels applying various freeze-drying and super critical CO2 drying techniques. Aerogels and foams can be used as porous templates. Tough ultra-high porosity foams prepared from cellulose I nanofibril suspensions were studied by Sehaqui et al. a wide range of mechanical properties including compression was obtained by controlling density and nanofibril interaction in the foams. CNCs could also be made to gel in water under low power sonication giving rise to aerogels with the highest reported surface area (>600m2/g) and lowest shrinkage during drying (6.5%) of cellulose aerogels. In another study by Aulin et al., the formation of structured porous aerogels of nanocellulose by freeze-drying was demonstrated. The density and surface texture of the aerogels was tuned by selecting the concentration of the nanocellulose dispersions before freeze-drying. Chemical vapour deposition of a fluorinated silane was used to uniformly coat the aerogel to tune their wetting properties towards non-polar liquids/oils.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.